home / stock / vcyt / vcyt quote
Last: | $21.26 |
---|---|
Change Percent: | -0.19% |
Open: | $21.37 |
Close: | $21.26 |
High: | $21.73 |
Low: | $21.1 |
Volume: | 574,463 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$21.26 | $21.37 | $21.26 | $21.73 | $21.1 | 574,463 | 07-02-2024 |
$21.33 | $21.59 | $21.33 | $22.11 | $21.175 | 758,916 | 07-01-2024 |
$21.67 | $22.1 | $21.67 | $22.12 | $21.13 | 1,632,046 | 06-28-2024 |
$21.99 | $22.66 | $21.99 | $22.93 | $21.97 | 879,088 | 06-27-2024 |
$22.5 | $22.55 | $22.5 | $22.83 | $22.205 | 660,114 | 06-26-2024 |
$22.73 | $22.86 | $22.73 | $23.09 | $22.61 | 669,322 | 06-25-2024 |
$22.94 | $22.63 | $22.94 | $23.23 | $22.63 | 835,841 | 06-24-2024 |
$22.54 | $21.85 | $22.54 | $22.55 | $21.81 | 3,307,731 | 06-21-2024 |
$21.76 | $21.22 | $21.76 | $21.98 | $20.85 | 617,775 | 06-20-2024 |
$21.41 | $21.36 | $21.41 | $21.43 | $20.9 | 579,213 | 06-19-2024 |
$21.41 | $21.36 | $21.41 | $21.43 | $20.9 | 579,213 | 06-18-2024 |
$21.38 | $20.85 | $21.38 | $21.42 | $20.52 | 807,935 | 06-17-2024 |
$20.97 | $21.28 | $20.97 | $21.47 | $20.69 | 915,885 | 06-14-2024 |
$21.79 | $21.97 | $21.79 | $22.14 | $21.47 | 641,935 | 06-13-2024 |
$22.07 | $22.12 | $22.07 | $22.67 | $21.68 | 845,222 | 06-12-2024 |
$21.29 | $20.59 | $21.29 | $21.33 | $20.59 | 558,635 | 06-11-2024 |
$20.88 | $20.21 | $20.88 | $20.9 | $19.86 | 769,418 | 06-10-2024 |
$20.65 | $20.97 | $20.65 | $21.095 | $20.56 | 470,343 | 06-07-2024 |
$21.41 | $21.55 | $21.41 | $21.76 | $21.4 | 522,827 | 06-06-2024 |
$21.81 | $21.48 | $21.81 | $22.17 | $21.28 | 573,763 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Findings presented at the ENDO 2024 conference Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive d...
Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from three studies will demonstrate the power of the Afirma GRID (Genomic Resource for Intelligent Discovery) tool to help unlock new molecular insights into thyroid tumors, which may ultimately help...
Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong s...